Omnicell (OMCL) Receives a Rating Update from a Top Analyst

By Carrie Williams

Cantor Fitzgerald analyst Steven Halper reiterated a Buy rating on Omnicell (OMCLResearch Report) today and set a price target of $80. The company’s shares opened today at $70.59.

Halper noted:

“. We continue to rate OMCL shares at Overweight but increase our 12-month price target to $80 from $70. We recently attended the mid- year meeting of the Pharmacists (ASHP). ASHP is the company’s most important trade show. During the show, the company hosted a small analyst event and highlighted its newest product offerings. Specifically, it appears as though the company is making good progress with its XR2 and IVX automation products. However, the key focus appears to be on software and data analytics, in order to create work flow efficiencies for hospitals and pharmacies.”

According to, Halper is a top 25 analyst with an average return of 20.9% and a 69.7% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.

Omnicell has an analyst consensus of Strong Buy, with a price target consensus of $72.20.

See today’s analyst top recommended stocks >>

Omnicell’s market cap is currently $2.96B and has a P/E ratio of 63.13. The company has a Price to Book ratio of 4.78.

Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omnicell, Inc. engages in the provision of automation and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.